Literature DB >> 12771726

Immunocytochemical analysis of prostate stem cell antigen as adjunct marker for detection of urothelial transitional cell carcinoma in voided urine specimens.

Lirong Cheng1, Robert E Reiter, Yusheng Jin, Hirschowitz Sharon, Jeffrey Wieder, Timothy F Lane, Jianyu Rao.   

Abstract

PURPOSE: Prostate stem cell antigen (PSCA), a homologue of the Ly-6/Thy-1 family of cell surface antigens, has been shown to be increased in a majority of human transitional cell carcinomas. We tested the possibility of using PSCA as an adjunct marker for urine cytology.
MATERIALS AND METHODS: Immunocytochemical analysis was performed on 44 archived voided urine samples obtained from 3 groups of patients based on initial voided urine cytological results and subsequent followup biopsy findings. Group 1 (14 of 44 patients) had positive findings on cytology and histology, group 2 (16 of 44) had negative cytology but positive histology, and group 3 (14 of 44) had negative findings on cytology and histology. Cytological slides prepared from 10 fresh voided urine samples were also analyzed. Papanicoloau stained archived urine slides were de-stained and re-stained immunocytochemically with a monoclonal antibody against PSCA. Immunofluorescence followed by laser scanning cytometer analysis was also performed on archived slides from 2 representative cases.
RESULTS: Sensitivity and specificity were 46.7% and 100% for cytology alone, respectively, and 80% and 85.7% for PSCA alone, respectively. PSCA immunostaining was positive in 92.8% group 1, 68.8% group 2 and only 14.3% group 3 samples. The difference in positive PSCA findings in groups 2 and 3 were statistically significant at p <0.01 by chi-square test. Whereas some superficial umbrella cells showed slight staining by immunocytochemistry, it was feasible to distinguish the expression levels between tumor and normal superficial umbrella cells quantitatively using immunofluorescence coupled with laser scan cytometry analysis.
CONCLUSIONS: Immunocytochemical analysis of PSCA on archived voided urine samples may provide a simple and quantitative adjunct marker for cytological diagnosis of urothelial carcinoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12771726     DOI: 10.1097/01.ju.0000064929.43602.17

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

Review 1.  Prostate stem cell antigen: a Jekyll and Hyde molecule?

Authors:  Norihisa Saeki; Jian Gu; Teruhiko Yoshida; Xifeng Wu
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

2.  Prostate stem cell antigen variation rs2294008 associated with the risk of bladder cancer.

Authors:  Maomao Li; Xi Yu; Liangliang Cheng; Yi Huang; Guobin Weng
Journal:  Int J Clin Exp Med       Date:  2015-08-15

3.  Effects of PSCA rs2294008 (C/T) and c-MYC rs9642880 (G/T) polymorphisms on bladder cancer: evidence from a meta-analysis.

Authors:  Jie Gao; Peng-Tao Yang; Yan Diao; Hua-Feng Kang; Yang Zhao; Shuai Lin; Zi-Ming Wang; Meng Wang; Xi-Jing Wang; Zhi-Jun Dai
Journal:  Int J Clin Exp Med       Date:  2015-02-15

4.  Armed and targeted measles virus for chemovirotherapy of pancreatic cancer.

Authors:  S Bossow; C Grossardt; A Temme; M F Leber; S Sawall; E P Rieber; R Cattaneo; C von Kalle; G Ungerechts
Journal:  Cancer Gene Ther       Date:  2011-06-24       Impact factor: 5.987

5.  Urine cytology and adjunct markers for detection and surveillance of bladder cancer.

Authors:  Peggy S Sullivan; Jessica B Chan; Mary R Levin; Jianyu Rao
Journal:  Am J Transl Res       Date:  2010-07-25       Impact factor: 4.060

Review 6.  Novel Redirected T-Cell Immunotherapies for Advanced Prostate Cancer.

Authors:  Tanya B Dorff; Vivek Narayan; Stephen J Forman; Peter D Zang; Joseph A Fraietta; Carl H June; Naomi B Haas; Saul J Priceman
Journal:  Clin Cancer Res       Date:  2022-02-15       Impact factor: 13.801

7.  Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer.

Authors:  Xifeng Wu; Yuanqing Ye; Lambertus A Kiemeney; Patrick Sulem; Thorunn Rafnar; Giuseppe Matullo; Daniela Seminara; Teruhiko Yoshida; Norihisa Saeki; Angeline S Andrew; Colin P Dinney; Bogdan Czerniak; Zuo-feng Zhang; Anne E Kiltie; D Timothy Bishop; Paolo Vineis; Stefano Porru; Frank Buntinx; Eliane Kellen; Maurice P Zeegers; Rajiv Kumar; Peter Rudnai; Eugene Gurzau; Kvetoslava Koppova; Jose Ignacio Mayordomo; Manuel Sanchez; Berta Saez; Annika Lindblom; Petra de Verdier; Gunnar Steineck; Gordon B Mills; Alan Schned; Simonetta Guarrera; Silvia Polidoro; Shen-Chih Chang; Jie Lin; David W Chang; Katherine S Hale; Tadeusz Majewski; H Barton Grossman; Steinunn Thorlacius; Unnur Thorsteinsdottir; Katja K H Aben; J Alfred Witjes; Kari Stefansson; Christopher I Amos; Margaret R Karagas; Jian Gu
Journal:  Nat Genet       Date:  2009-08-02       Impact factor: 38.330

Review 8.  The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer.

Authors:  Ilhan Karaoglu; Antoine G van der Heijden; J Alfred Witjes
Journal:  World J Urol       Date:  2013-10-29       Impact factor: 4.226

9.  Association between PSCA mRNA expression levels and rs2294008 polymorphism in transitional cell cancer of the bladder.

Authors:  Kewen Zheng; Zhigang Chen; Ye Tian; Gangyue Hao
Journal:  Oncol Lett       Date:  2014-11-24       Impact factor: 2.967

10.  Genetic variant as a selection marker for anti-prostate stem cell antigen immunotherapy of bladder cancer.

Authors:  Indu Kohaar; Patricia Porter-Gill; Petra Lenz; Yi-Ping Fu; Adam Mumy; Wei Tang; Andrea B Apolo; Nathaniel Rothman; Dalsu Baris; Alan R Schned; Kris Ylaya; Molly Schwenn; Alison Johnson; Michael Jones; Masatoshi Kida; Debra T Silverman; Stephen M Hewitt; Lee E Moore; Ludmila Prokunina-Olsson
Journal:  J Natl Cancer Inst       Date:  2012-12-23       Impact factor: 13.506

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.